Multiple-dose Pharmacokinetics of Doripenem During Continuous Venovenous Hemodiafiltration and Molecular Adsorbent Recirculating System in ICU Patients and During Hemodialysis in Longterm Hemodialysis Patients.

Inclusion Criteria:

• Age >18 years
• Suspected or proven bacterial infection requiring parenteral antibiotic therapy.
• Organ replacement therapy (MARS, CVVHDF or HD)

Exclusion Criteria:

• Known hypersensitivity to doripenem or other carbapenems, or severe hypersensitivity (anaphylactic reaction) to beta-lactam antibacterial agents.
• An expected survival of less than two days.
• Known pregnancy
• Coadministration of valproic acid or probenecid, which cannot be discontinued for the duration of the study
• Doripenem as monotherapy for resistent species or fungal infections.
• Other reasons opposing the study participation on the discretion of the investigators.